New York greenlights a groundbreaking clinical trial of a THC-based oral solution, VER-01, targeting chronic sciatica pain—a move with national medical cannabis implications.

Georgia, Vermont and California officials say DEA has offered little implementation guidance after marijuana moved to Schedule III for state medical programs, leaving labeling, taxes and inspections unclear.

A plain‑English guide to how culture, compliance, and licensing collide in weed delivery — and what DC, Maryland, and Virginia residents should watch now.

A long-delayed Texas rule banning most hemp THC products is now in effect after a state Supreme Court decision, with felony penalties and ripple effects beyond Texas.

New York’s legal cannabis market is tracking toward a new annual high while early indicators point to a cooling trend. Here’s what that mix of growth and hesitation could mean for delivery, compliance, and DMV operators watching from the sidelines.

Four Republican senators signaled no interest in rethinking a looming federal clampdown on hemp-derived cannabinoids, citing alleged Chinese involvement, per MJBizDaily.

High Times spotlights four cannabis attorneys navigating 280E taxes, the trademark gap, Farm Bill fallout, and the moral cost of building an industry while people remain incarcerated.

A DEA administrative judge paused the cannabis rescheduling hearing to consider a GAO watchdog report on process gaps. A DEA response is due by October 13, adding delay and uncertainty.

Latest polling shows voters overwhelmingly opposing Question 8 as the election approaches, signaling strong support for adult-use markets.

DEA issued a scheduling order for five tryptamines as FDA momentum grows, including breakthrough status for a 4‑OH‑DiPT drug candidate aimed at postpartum depression.

A new federal court ruling, recalls, and retail trends are shifting risk and opportunity for cannabis delivery apps, couriers, and investors across the DMV.

Bipartisan federal moves and a new Louisiana pilot are reshaping psychedelic therapy research. Here’s how it intersects with dc cannabis research, patient access, and safety.

NORML’s new op-ed challenges The New York Times’ framing of cannabis. Here’s why that media narrative matters for delivery rules, licensing, and consumer safety in the DMV.

TerrAscend expands its New Jersey footprint with a $9 million cash-and-debt purchase, bringing the MSO to five Garden State stores and signaling more consolidation ahead.

Alabama health officials unanimously withdrew their objection to potential federal rescheduling of medical cannabis, while the state program continues despite cannabis remaining Schedule I under Alabama law.

MJBizDaily reports a federal hemp THC ban extension is on deck. Here’s why blanket cannabinoid bans rarely work — and how operators can use the runway, with DMV-specific guidance.

Journalist Erica Rex urges caution: psychedelic states can open trauma and power imbalances. Here’s what ethical care, safety, and patient-centered practices should look like in the DMV.

A new federal push to speed psychedelic therapies highlights ibogaine and VA trials, but funding cuts, workforce gaps, and ethics could slow real-world access.

A new documentary spotlights ketamine-assisted therapy for firefighters and raises hard questions about evidence, ethics, and how advocacy should meet science.

A new nonprofit, After The Story, will fund legal psychedelic-assisted care and integration for reporters and media workers carrying trauma from the job.